B. Riley resumed coverage of Augmedix with a Buy rating and $5.50 price target. After Nuance’s $20B acquisition by Microsof (MSFT), Augmedix is “one of a kind” as a publicly traded company focusing on providing medical documentation services to clinicians, the analyst tells investors in a research note. The firm believes the recent selling pressure in the shares has created an entry opportunity. Augmedix is currently trading at a deep discount to peer private-held medical documentation companies, says B. Riley.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix price target lowered to $4.50 from $6.50 at Evercore ISI
- Augmedix price target lowered to $5 from $6.50 at Maxim
- Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
- Augmedix sees FY24 revenue $60M-$62M, consensus $61.53M
- Augmedix reports Q4 EPS (9c), consensus (10c)
